Among different endothelial cells we examined, only circulating CD34+CD133+ EPCs showed dose-dependent protective effects against AD development, especially in the presence of HTN and CMB (Tables 1 and 2; Figure 2). This evidence concerns the gene CD34 and Alzheimer disease.